Cisplatin in cancer therapy: Molecular mechanisms of action

Abrams, 2003, SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer, Mol. Cancer Ther., 2, 471 Agarwal, 2003, Ovarian cancer: strategies for overcoming resistance to chemotherapy, Nat. Rev. Cancer, 3, 502, 10.1038/nrc1123 Aggarwal, 1993, A histochemical approach to the mechanism of action of cisplatin and its analogues, J. Histochem. Cytochem., 41, 1053, 10.1177/41.7.8515048 Aggarwal, 1998, Calcium modulation of toxicities due to cisplatin, Met. Based Drugs, 5, 77, 10.1155/MBD.1998.77 Aggarwal, 1980, Platinum drugs: combined anti-lymphoproliferative and nephrotoxicity assay in rats, Cancer Chemother. Pharmacol., 4, 249, 10.1007/BF00255269 Ajani, 2008, Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial, JAMA, 299, 1914, 10.1001/jama.299.16.1914 Akron. 2009. The Chemical Database. The Department of Chemistry at the University of Akron.〈http://ull.chemistry.uakron.edu/erd〉 and search on CAS number. (accessed 25.03.14.). Alberts, 1981, Adriamycin/cis-platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland, Cancer, 47, 645, 10.1002/1097-0142(19810215)47:4<645::AID-CNCR2820470404>3.0.CO;2-A Al-Majed, 2007, Carnitine deficiency provokes cisplatin-induced hepatotoxicity in rats, Basic Clin. Pharmacol. Toxicol., 100, 145, 10.1111/j.1742-7843.2006.00024.x Al-Majed, 2006, Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model, Pharmacol. Res., 53, 278, 10.1016/j.phrs.2005.12.005 Alizadehnohi, 2012, The synergistic cytotoxic effect of cisplatin and honey bee venom on human ovarian cancer cell line A2780cp, J. Venom. Res., 3, 22 Apostolou, 2013, AnvirzelTM in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines, BMC Pharmacol. Toxicol., 14, 18, 10.1186/2050-6511-14-18 Arany, 2003, Cisplatin nephrotoxicity, Semin. Nephrol., 23, 460, 10.1016/S0270-9295(03)00089-5 Ardizzoni, 1991, Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian lung cancer task force (FONICAP) phase II study, Cancer, 67, 2984, 10.1002/1097-0142(19910615)67:12<2984::AID-CNCR2820671208>3.0.CO;2-Q Arts, 1999, Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis, Int. J. Cancer, 84, 234, 10.1002/(SICI)1097-0215(19990621)84:3<234::AID-IJC6>3.0.CO;2-9 Baniahmad, 1993, Mechanisms of transcriptional activation by steroid hormone receptors, J. Cell. Biochem., 51, 151, 10.1002/jcb.240510206 Basch, 1986, Binding of Pt(NH3)32+ to nucleic acid bases, Inorg. Chem., 25, 684, 10.1021/ic00225a019 Basu, 1993, The potential of protein kinase C as a target for anticancer treatment, Pharmacol. Ther., 59, 257, 10.1016/0163-7258(93)90070-T Basu, 2010, Cellular responses to cisplatin-induced DNA damage, J. Nucleic Acids, 2010 Basu, 2007, Protein kinase cepsilon makes the life and death decision, Cell. Signal., 19, 1633, 10.1016/j.cellsig.2007.04.008 Basu, 2005, Activation of ERK during DNA damage-induced apoptosis involves protein kinase Cdelta, Biochem. Biophys. Res. Commun., 334, 1068, 10.1016/j.bbrc.2005.06.199 Beck, 1973, Effect of cis-platinum(II)diamminodichloride on wild type and deoxyribonucleic acid repair deficient mutants of Escherichia coli, J. Bacteriol., 116, 1247, 10.1128/JB.116.3.1247-1252.1973 Belfi, 1999, Increased sensitivity of human colon cancer cells to DNA cross-linking agents after GRP78 up-regulation, Biochem. Biophys. Res. Commun., 257, 361, 10.1006/bbrc.1999.0472 Bertolini, 2009, Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment, Proc. Natl. Acad. Sci. U.S.A., 106, 16281, 10.1073/pnas.0905653106 Brazil, 2001, Ten years of protein kinase B signalling: a hard Akt to follow, Trends Biochem. Sci., 26, 657, 10.1016/S0968-0004(01)01958-2 Brozovic, 2010, The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin, Crit. Rev. Toxicol., 40, 347, 10.3109/10408441003601836 Brozovic, 2001, Induction of heat shock protein 70 in drug-resistant cells by anticancer drugs and hyperthermia, Neoplasma, 48, 99 Byun, 2013, Tetraarsenic oxide and cisplatin induce apoptotic synergism in cervical cancer, Oncol. Rep., 29, 1540, 10.3892/or.2013.2243 Canetta, 1985, Carboplatin: the clinical spectrum to date, Cancer Treat. Rev., 12, S125, 10.1016/0305-7372(85)90027-1 Carloni, 1996, Platinum-modified nucleobase pairs in the solid state: a theoretical study, J. Phys. Chem., 100, 17797, 10.1021/jp961738z Carloni, 2000, Key steps of the cis-platin–DNA interaction: density functional theory-based molecular dynamics simulations, J. Phys. Chem. B, 104, 823, 10.1021/jp992590x Caro, 2004, Oxidative stress, toxicology, and pharmacology of CYP2E1, Annu. Rev. Pharmacol. Toxicol., 44, 27, 10.1146/annurev.pharmtox.44.101802.121704 Cetin, 2006, Cisplatin impairs antioxidant system and causes oxidation in rat kidney tissues: possible protective roles of natural antioxidant foods, J. Appl. Toxicol., 26, 42, 10.1002/jat.1103 Chian, 2014, Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the nrf2 pathway, Asian Pac. J. Cancer Prev., 15, 2911, 10.7314/APJCP.2014.15.6.2911 Chang, 2001, Mammalian MAP kinase signalling cascades, Nature, 410, 37, 10.1038/35065000 Chen, 2009, Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer, J. Clin. Oncol., 27, 1401, 10.1200/JCO.2008.20.2127 Cho, 2008, Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance, Cancer Lett., 260, 96, 10.1016/j.canlet.2007.10.022 Colombo, 1986, Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary, Obstet. Gynecol., 67, 265, 10.1097/00006250-198602000-00020 Creagan, 1983, Cyclophosphamide, adriamycin, and cis-diamminedichloroplatinum (II) in the treatment of advanced nonsquamous cell head and neck cancer, Cancer, 52, 2007, 10.1002/1097-0142(19831201)52:11<2007::AID-CNCR2820521106>3.0.CO;2-T Crino, 1997, Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study, J. Clin. Oncol., 15, 297, 10.1200/JCO.1997.15.1.297 Cuadrado, 2007, A new p38 MAP kinase-regulated transcriptional coactivator that stimulates p53-dependent apoptosis, EMBO J., 26, 2115, 10.1038/sj.emboj.7601657 Cummings, 2000, Expression of glutathione-dependent enzymes and cytochrome P450s in freshly isolated and primary cultures of proximal tubular cells from human kidney, J. Pharmacol. Exp. Ther., 293, 677 de Jongh, 2003, Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients, Br. J. Cancer, 88, 1199, 10.1038/sj.bjc.6600884 Decatris, 2004, Platinum-based chemotherapy in metastatic breast cancer: current status, Cancer Treat. Rev., 30, 53, 10.1016/S0305-7372(03)00139-7 DeHaan, 2001, Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase, Cancer Chemother. Pharmacol., 48, 383, 10.1007/s002800100318 Deng, 2013, Synergistic interaction of beta-galactosyl-pyrrolidinyl diazeniumdiolate with cisplatin against three tumor cells, Arch. Pharm. Res., 36, 619, 10.1007/s12272-013-0047-0 Desoize, 2002, Cancer and metals and metal compounds: part I--carcinogenesis, Crit. Rev. Oncol. Hematol., 42, 1, 10.1016/S1040-8428(02)00017-3 Desoize, 2002, Particular aspects of platinum compounds used at present in cancer treatment, Crit. Rev. Oncol. Hematol., 42, 317, 10.1016/S1040-8428(01)00219-0 Deubel, 2002, On the competition of the purine bases, functionalities of peptide side chains, and protecting agents for the coordination sites of dicationic cisplatin derivatives, J. Am. Chem. Soc., 124, 5834, 10.1021/ja012221q Deubel, 2004, Factors governing the kinetic competition of nitrogen and sulfur ligands in cisplatin binding to biological targets, J. Am. Chem. Soc., 126, 5999, 10.1021/ja0499602 Dexeus, 1991, Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract, J. Urol., 146, 1284, 10.1016/S0022-5347(17)38069-2 Dhar, 2011, Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo, Proc. Natl. Acad. Sci. U.S.A., 108, 1850, 10.1073/pnas.1011379108 Dimery, 1990, Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma, J. Clin. Oncol., 8, 1056, 10.1200/JCO.1990.8.6.1056 dos Santos, 2007, Dimethylthiourea protects against mitochondrial oxidative damage induced by cisplatin in liver of rats, Chem. Biol. Interact., 170, 177, 10.1016/j.cbi.2007.07.014 Dreyfuss, 1987, Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin, Cancer, 60, 2869, 10.1002/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0.CO;2-Y Du, 2013, Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancermediated malignant pleural effusion, Oncol. Rep., 29, 2332, 10.3892/or.2013.2349 Einzig, 1991, A phase II study of taxol in patients with malignant melanoma, Investig. New Drugs, 9, 59, 10.1007/BF00194546 Einzig, 1992, Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma, J. Clin. Oncol., 10, 1748, 10.1200/JCO.1992.10.11.1748 Eisenberger, 1985, Supporting evidence for an active treatment program for advanced salivary gland carcinomas, Cancer Treat. Rep., 69, 319 Forastiere, 1994, Paclitaxel (Taxol) for the treatment of head and neck cancer, Semin. Oncol., 21, 49 Fraval, 1978, Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus luteus, Mutat. Res., 51, 121, 10.1016/0027-5107(78)90014-3 Frezza, 2010, Novel metals and metal complexes as platforms for cancer therapy, Curr. Pharm. Des., 16, 1813, 10.2174/138161210791209009 Fujii, 1979, Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents, Gann, 70, 209 Go, 1999, Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin, J. Clin. Oncol., 17, 409, 10.1200/JCO.1999.17.1.409 Gong, 1999, The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage, Nature, 399, 806, 10.1038/21690 Gottesman, 2002, Multidrug resistance in cancer: role of ATP-dependent transporters, Nat. Rev. Cancer, 2, 48, 10.1038/nrc706 Goodsell, 2006, The molecular perspective: cisplatin, Stem Cells, 24, 514, 10.1634/stemcells.2006-CSC2 Gupta, 2012, Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy, Antioxid. Redox Signal., 16, 1295, 10.1089/ars.2011.4414 Hampton, 1997, Dual regulation of caspase activity by hydrogen peroxide: implications for apoptosis, FEBS Lett., 414, 552, 10.1016/S0014-5793(97)01068-5 Hartmann, 2000, A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors, Investig. New Drugs, 18, 281, 10.1023/A:1006490226104 Hartmann, 2003, Toxicity of platinum compounds, Expert Opin. Pharmacother., 4, 889, 10.1517/14656566.4.6.889 Hayakawa, 2004, Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress, Mol. Cell., 16, 521, 10.1016/j.molcel.2004.10.024 Hayakawa, 1999, Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line, J. Biol. Chem., 274, 31648, 10.1074/jbc.274.44.31648 Hayakawa, 2000, Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin, Cancer Res., 60, 5988 Hazardous Substances Data Bank.National Library of Medicine. 〈http://toxnet.nlm.nih.gov/ cgi-bin/sis/htmlgen〉?HSDB and search on CAS number. (accessed 19.03.14.). Hirata, 1993, Modulation of sensitivity of human ovarian cancer cells to cis-diamminedichloroplatinum(II) by 12-O-tetradecanoylphorbol-13-acetate and D,L-buthionine-S,R-sulphoximine, Int. J. Cancer, 55, 521, 10.1002/ijc.2910550332 Hitt, 1998, Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck, Ann. Oncol., 9, 1347, 10.1023/A:1008413818569 Holmes, 1991, Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer, J. Natl. Cancer Inst., 83, 1797, 10.1093/jnci/83.24.1797-a Holzer, 2006, Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin, Mol. Pharmacol., 70, 1390, 10.1124/mol.106.022624 Huang, 2000, Changes in p21WAF1, pRb, Mdm-2, Bax and Bcl-2 expression in cervical cancer cell lines transfected with a p53 expressing adenovirus, Eur. J. Cancer, 36, 249, 10.1016/S0959-8049(99)00247-6 IARC, 1981, Cisplatin. In Some Antineoplastic and Immunosuppressive Agents, 151 Ichinose, 1995, A phase II trial of oral tegafur and uracil plus cisplatin in patients with inoperable non small cell lung cancer, Cancer, 75, 2677, 10.1002/1097-0142(19950601)75:11<2677::AID-CNCR2820751106>3.0.CO;2-D Ichinose, 2000, UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma: a multiinstitutional phase II trial. For the Japan UFT Lung Cancer Study Group, Cancer, 88, 318, 10.1002/(SICI)1097-0142(20000115)88:2<318::AID-CNCR11>3.0.CO;2-6 Iraz, 2005, Aminoguanidine prevents ototoxicity induced by cisplatin in rats, Ann. Clin. Lab. Sci., 35, 329 Iseri, 2007, Simvastatin attenuates cisplatin-induced kidney and liver damage in rats, Toxicology, 230, 256, 10.1016/j.tox.2006.11.073 Ishida, 2002, Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals, Proc. Natl. Acad. Sci. U.S.A., 99, 14298, 10.1073/pnas.162491399 Isonishi, 1990, Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate, J. Biol. Chem., 265, 3623, 10.1016/S0021-9258(19)39638-3 Iwasaki, 2005, Double-cycle, high-dose ifosfamide, carboplatin, and etoposide followed by peripheral blood stem-cell transplantation for small cell lung cancer, Chest, 128, 2268, 10.1378/chest.128.4.2268 Jennerwein, 1995, Effect of intracellular chloride on the cellular pharmacodynamics of cis-diamminedichloroplatinum(II), Drug Metab. Dispos., 23, 178 Johnson, 2002, Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases, Science, 298, 1911, 10.1126/science.1072682 Johnson, 1996, Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines, Exp. Cell Res., 226, 133, 10.1006/excr.1996.0211 Jones, 2007, Regulation of p73-mediated apoptosis by c-Jun N-terminal kinase, Biochem. J., 405, 617, 10.1042/BJ20061778 Kakar, 2012, Synergistic cytotoxic action of cisplatin and withaferin A on ovarian cancer cell lines, Biochem. Biophys. Res. Commun., 423, 819, 10.1016/j.bbrc.2012.06.047 Kart, 2010, Caffeic acid phenethyl ester (CAPE) ameliorates cisplatin-induced hepatotoxicity in rabbit, Exp. Toxicol. Pathol., 62, 45, 10.1016/j.etp.2009.02.066 Kelland, 2007, The resurgence of platinum-based cancer chemotherapy, Nat. Rev. Cancer, 7, 573, 10.1038/nrc2167 Khan, 1982, Cisplatin therapy in recurrent childhood brain tumors, Cancer Treat. Rep., 66, 2013 Kharbanda, 2000, Activation of MEK kinase 1 by the c-Abl protein tyrosine kinase in response to DNA damage, Mol. Cell. Biol., 20, 4979, 10.1128/MCB.20.14.4979-4989.2000 Kim, 1999, Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma, Cancer, 85, 295, 10.1002/(SICI)1097-0142(19990115)85:2<295::AID-CNCR5>3.0.CO;2-H Kischkel, 1995, Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor, EMBO J., 14, 5579, 10.1002/j.1460-2075.1995.tb00245.x Koch, 2013, Overcoming chemotherapy resistance of ovarian cancer cells by liposomal cisplatin: molecular mechanisms unveiled by gene expression profiling, Biochem. Pharmacol., 85, 1077, 10.1016/j.bcp.2013.01.028 Koizumi, 2008, S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial, Lancet Oncol., 9, 215, 10.1016/S1470-2045(08)70035-4 Kosmas, 2001, Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer, J. Clin. Oncol., 19, 119, 10.1200/JCO.2001.19.1.119 Kuhlmann, 1997, Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application, Nephrol. Dial. Transplant., 12, 2478, 10.1093/ndt/12.12.2478 Lau, 2005, Hydrolysis of the anticancer drug cisplatin: pitfalls in the interpretation of quantum chemical calculations, J. Chem. Theory Comput., 2, 103, 10.1021/ct050229a Le, 1994, Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients, J. Clin. Oncol., 12, 360, 10.1200/JCO.1994.12.2.360 Legha, 1990, A phase II trial of taxol in metastatic melanoma, Cancer, 65, 2478, 10.1002/1097-0142(19900601)65:11<2478::AID-CNCR2820651114>3.0.CO;2-S Levy, 2008, Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage, Mol. Cell., 29, 350, 10.1016/j.molcel.2007.12.022 Liao, 2008, Selection of agents for prevention of cisplatin-induced hepatotoxicity, Pharmacol. Res., 57, 125, 10.1016/j.phrs.2008.01.001 Light, 1997, Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system, Cancer Res., 57, 3759 Lin, 2013, Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway, Am. J. Respir. Cell Mol. Biol., 49, 241, 10.1165/rcmb.2012-0244OC Lin, 2014, Downregulation of HIPK2 increases resistance of bladder cancer cell to cisplatin by regulating Wip1, PLoS One, 9, e98418, 10.1371/journal.pone.0098418 Lin, 2002, The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae, Mol. Pharmacol., 62, 1154, 10.1124/mol.62.5.1154 Liu, 2002, Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance, Cancer Res., 62, 924 Llanos, 2010, Depletion of ribosomal protein L37 occurs in response to DNA damage and activates p53 through the L11/MDM2 pathway, Cell Cycle, 9, 4005, 10.4161/cc.9.19.13299 Lynch, 2009, Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management, Mol. Oncol., 3, 97, 10.1016/j.molonc.2009.02.004 Machuy, 2004, Requirement of caspase-mediated cleavage of c-Abl during stress-induced apoptosis, Cell Death. Differ., 11, 290, 10.1038/sj.cdd.4401336 Mandic, 2003, Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling, J. Biol. Chem., 278, 9100, 10.1074/jbc.M210284200 Mansour, 2006, Silymarin modulates Cisplatin-induced oxidative stress and hepatotoxicity in rats, J. Biochem. Mol. Biol., 39, 656 Mantri, 2006, Computational Studies: Cisplatin Marshall, 1995, Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation, Cell, 80, 179, 10.1016/0092-8674(95)90401-8 Martindale, 2002, Cellular response to oxidative stress: signaling for suicide and survival, J. Cell. Physiol., 192, 1, 10.1002/jcp.10119 Matsuki, 2013, Pathological complete response to gemcitabine and cisplatin chemotherapy for advanced upper tract urothelial carcinoma: a case report, Nihon Hinyokika Gakkai Zasshi, 104, 33 McGuire, 1989, Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms, Ann. Intern. Med., 111, 273, 10.7326/0003-4819-111-4-273 McGuire, 1996, Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N. Engl. J. Med., 334, 1, 10.1056/NEJM199601043340101 Meng, 2013, Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2′-deoxycytidine on ovarian cancer, Br. J. Cancer, 108, 579, 10.1038/bjc.2013.10 Milczarek, 2013, Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin, Anticancer Res., 33, 433 Minami, 2013, Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells, Mol. Cancer Res., 11, 140, 10.1158/1541-7786.MCR-12-0401 Murphy, 1993, Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer, J. Natl. Cancer Inst., 85, 384, 10.1093/jnci/85.5.384 Nagpal, 2005, Noncalcemic actions of vitamin D receptor ligands, Endocr. Rev., 26, 662, 10.1210/er.2004-0002 Natarajan, 1999, Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited, Biochem. Pharmacol., 58, 1625, 10.1016/S0006-2952(99)00250-6 Naziroglu, 2004, Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats, Toxicology, 195, 221, 10.1016/j.tox.2003.10.012 Nehme, 1999, Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells, Br. J. Cancer, 79, 1104, 10.1038/sj.bjc.6690176 Nessa, 2011, Synergism from combinations of cisplatin and oxaliplatin with quercetin and thymoquinone in human ovarian tumour models, Anticancer Res., 31, 3789 Newton, 2003, Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm, Biochem. J., 370, 361, 10.1042/bj20021626 Nikolov, 1994, Molecular mechanical and quantum chemical study on the species involved in the hydrolysis of cis-diamminedichloroplatinum(II) and substituted bis(ethylenediamine)dichloroplatinum(II) complexes Part I. Reactants and products, Inorg. Chim. Acta, 217, 159, 10.1016/0020-1693(93)03765-3 Nishizuka, 1992, Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C, Science, 258, 607, 10.1126/science.1411571 Nowak, 2002, Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells, J. Biol. Chem., 277, 43377, 10.1074/jbc.M206373200 Nunez, 1998, Caspases: the proteases of the apoptotic pathway, Oncogene, 17, 3237, 10.1038/sj.onc.1202581 Ohta, 2006, Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models, Endocrinology, 147, 1761, 10.1210/en.2005-1450 Ozben, 2007, Oxidative stress and apoptosis: impact on cancer therapy, J. Pharm. Sci., 96, 2181, 10.1002/jps.20874 Pavankumar, 1999, Comprehensive ab initio quantum mechanical and molecular orbital (MO) analysis of cisplatin: structure, bonding, charge density, and vibrational frequencies, J. Comput. Chem., 20, 365, 10.1002/(SICI)1096-987X(199902)20:3<365::AID-JCC8>3.0.CO;2-1 Parkin, 2005, Global cancer statistics, 2002, CA Cancer J. Clin., 55, 74, 10.3322/canjclin.55.2.74 Parness, 1981, Taxol binds to polymerized tubulin in vitro, J. Cell Biol., 91, 479, 10.1083/jcb.91.2.479 Persons, 1999, Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin, Clin. Cancer Res., 5, 1007 Pignon, 2008, Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group, J. Clin. Oncol., 26, 3552, 10.1200/JCO.2007.13.9030 Pinto-Leite, 2013, Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer, Biomed. Pharmacother., 67, 116, 10.1016/j.biopha.2012.11.007 Previati, 2006, Cisplatin-induced apoptosis in human promyelocytic leukemia cells, Int. J. Mol. Med., 18, 511 Rodriguez-Fernandez, 2009, Fluorescent cisplatin analogues and cytotoxic activity, Curr. Med. Chem., 16, 4314, 10.2174/092986709789578169 Rosenberg, 1965, Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode, Nature, 205, 698, 10.1038/205698a0 Saad, 2004, Role of non-selective adenosine receptor blockade and phosphodiesterase inhibition in cisplatin-induced nephrogonadal toxicity in rats, Clin. Exp. Pharmacol. Physiol., 31, 862, 10.1111/j.1440-1681.2004.04127.x Salvesen, 2004, Caspase activation—stepping on the gas or releasing the brakes? Lessons from humans and flies, Oncogene, 23, 2774, 10.1038/sj.onc.1207522 Salvesen, 1997, Caspases: intracellular signaling by proteolysis, Cell, 91, 443, 10.1016/S0092-8674(00)80430-4 Saramaki, 2006, Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor, Nucleic Acids Res., 34, 543, 10.1093/nar/gkj460 Sarosy, 1992, Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer, J. Clin. Oncol., 10, 1165, 10.1200/JCO.1992.10.7.1165 Scher, 1992, A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study, J. Urol., 148, 1625 Shaili, 2014, Platinum anticancer drugs and photochemotherapeutic agents: recent advances and future developments, Sci. Prog., 97, 20, 10.3184/003685014X13904811808460 Shen, 2004, Identification of cytoskeletal [14C]carboplatin-binding proteins reveals reduced expression and disorganization of actin and filamin in cisplatin-resistant cell lines, Mol. Pharmacol., 66, 789, 10.1124/mol.66.4.789 Shen, 2006, Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance, Mol. Pharmacol., 69, 1383, 10.1124/mol.105.017525 Shen, 2012, Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes, Pharmacol. Rev., 64, 706, 10.1124/pr.111.005637 Shi, 2014, AQP5 silencing suppresses p38 MAPK signaling and improves drug resistance in colon cancer cells, Tumour Biol., 35, 7035, 10.1007/s13277-014-1956-3 Shrivastava, 2011, Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy, Mol. Cancer Ther., 10, 1161, 10.1158/1535-7163.MCT-10-1100 Siddik, 2003, Cisplatin: mode of cytotoxic action and molecular basis of resistance, Oncogene, 22, 7265, 10.1038/sj.onc.1206933 Siwinska, 2001, Potentiation of the antiproliferative effect in vitro of doxorubicin, cisplatin and genistein by new analogues of vitamin D, Anticancer Res., 21, 1925 Skvortsov, 2014, Rac1 as a potential therapeutic target for chemo-radioresistant head and neck squamous cell carcinomas (HNSCC), Br. J. Cancer, 110, 2677, 10.1038/bjc.2014.221 Smith, 2007, The proteomic analysis of cisplatin resistance in breast cancer cells, Oncol. Res., 16, 497, 10.3727/096504007783438358 Song, 2014, Inhibition of EGFR-induced glucose metabolism sensitizes chondrosarcoma cells to cisplatin, Tumour Biol., 35, 7017, 10.1007/s13277-014-1902-4 Stupp, 2009, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncol., 10, 459, 10.1016/S1470-2045(09)70025-7 Stupp, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N. Engl. J. Med., 352, 987, 10.1056/NEJMoa043330 Tang, 2010, c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2, Neoplasia, 12, 128, 10.1593/neo.91438 The chemical book database 〈http://www.chemicalbook.com/ProductIndex_EN.aspxand〉 searchon product details. (accessed 21.03.14.). Tsimberidou, 2009, Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial, J. Clin. Oncol., 27, 6243, 10.1200/JCO.2009.23.6018 Valle, 2010, Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer, N. Engl. J. Med., 362, 1273, 10.1056/NEJMoa0908721 Vargas-Roig, 1998, Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy, Int. J. Cancer, 79, 468, 10.1002/(SICI)1097-0215(19981023)79:5<468::AID-IJC4>3.0.CO;2-Z von der, 2005, Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer, J. Clin. Oncol., 23, 4602, 10.1200/JCO.2005.07.757 Wang, 2005, Cellular processing of platinum anticancer drugs, Nat. Rev. Drug Discov., 4, 307, 10.1038/nrd1691 Wang, 2014, Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/beta-catenin/Snail signaling pathway, Eur. J. Pharmacol., 723, 156, 10.1016/j.ejphar.2013.12.004 Wang, 2014, Role of autophagy in cisplatin resistance in ovarian cancer cells, J. Biol. Chem., 24, 17163, 10.1074/jbc.M114.558288 Wang, 2000, Requirement for ERK activation in cisplatin-induced apoptosis, J. Biol. Chem., 275, 39435, 10.1074/jbc.M004583200 Weiss, 1993, New cisplatin analogues in development. A review, Drugs, 46, 360, 10.2165/00003495-199346030-00003 Winograd-Katz, 2006, Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor, Oncogene, 25, 7381, 10.1038/sj.onc.1209737 Xu, 2013, Combined anticancer activity of osthole and cisplatin in NCI-H460 lung cancer cells in vitro, Exp. Ther. Med., 5, 707, 10.3892/etm.2013.889 Yao, 2007, Cisplatin nephrotoxicity: a review, Am. J. Med. Sci., 334, 115, 10.1097/MAJ.0b013e31812dfe1e Yeh, 2002, Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation, Biochem.Pharmacol., 63, 1423, 10.1016/S0006-2952(02)00908-5 Yilmaz, 2004, The effects of erdosteine on the activities of some metabolic enzymes during cisplatin-induced nephrotoxicity in rats, Pharmacol. Res., 50, 287, 10.1016/j.phrs.2004.03.003 Yilmaz, 2005, The activities of liver adenosine deaminase, xanthine oxidase, catalase, superoxide dismutase enzymes and the levels of malondialdehyde and nitric oxide after cisplatin toxicity in rats: protective effect of caffeic acid phenethyl ester, Toxicol. Ind. Health, 21, 67, 10.1191/0748233705th216oa Youlden, 2008, The international epidemiology of lung cancer: geographical distribution and secular trends, J. Thorac. Oncol., 3, 819, 10.1097/JTO.0b013e31818020eb Yousef, 2009, Protective effect of grape seed proanthocyanidin extract against oxidative stress induced by cisplatin in rats, Food Chem. Toxicol., 47, 1176, 10.1016/j.fct.2009.02.007 Zhang, 2001, Hydrolysis theory for cisplatin and its analogues based on density functional studies, J. Am. Chem. Soc., 123, 9378, 10.1021/ja0023938